Icon is again reducing its revenue expectations for 2015 but increasing its profit guidance, counting on a big quarter of business wins to balance some sluggish backlog conversion.
CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.
Icon came through with double-digit revenue growth in the first quarter, but currency fluctuations have the Irish CRO scaling back its expectations for the full year.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
Global CRO Icon is launching a new service catered to the specific needs of medical device and diagnostic developers, touting one of its recent acquisitions as key to the move.
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015.
Irish CRO Icon is expanding its drug launch and marketing services, trading $120 million in cash for MediMedia Pharma Solutions.
Irish CRO Icon is plotting a new so-called innovation hub in its native Ireland, planning to hire 200 workers as it builds out a data-minded expansion.
Many clinical trials rely on patient-reported outcomes to determine whether drugs are working, but with disparate methods employed across the industry, it can be difficult to compare the results from one study with those of another. With that in mind, the FDA has recruited CRO giant Icon to help develop an industry standard for patient polling in antibacterial R&D.